Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, With Byetta as an Open Label Active Reference, in Subjects With Type 2 Diabetes Mellitus
Brief Summary: This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks,and less frequent follow-up visits for an additional 10 weeks. Assessments include repeat blood sampling and monitoring of any side effects.


Options:
A: Arm Label: Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: metformin | Arm Label: Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: liraglutide | Arm Label: Sita -> Sita; Type: ACTIVE_COMPARATOR; Interventions: Drug: sitagliptin, Drug: metformin | Arm Label: Sita -> Sita -> Lira 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: sitagliptin, Drug: metformin | Arm Label: Sita -> Sita -> Lira 1.8 mg; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin, Drug: metformin, Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg, Sita -> Sita -> Lira 1.2 mg | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): Sita -> Sita, Sita -> Sita -> Lira 1.2 mg, Sita -> Sita -> Lira 1.8 mg | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg, Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg, Sita -> Sita, Sita -> Sita -> Lira 1.2 mg, Sita -> Sita -> Lira 1.8 mg | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg, Sita -> Sita -> Lira 1.8 mg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: taspoglutide | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: taspoglutide; Assigned to Arm(s): 5
C: Intervention Type: DRUG; Name: Albiglutide (GSK716155) or exenatide; Assigned to Arm(s): N/A
D: Arm Label: Exenatide Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: exenatide, long acting release | Arm Label: Exenatide Twice Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: exenatide, long acting release; Assigned to Arm(s): Exenatide Once Weekly | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide Twice Daily

Answer: C